IsoRay's GliaSite Approved for Sale in 31 European Countries

IsoRay Inc. (NYSE: ISR) today announced that the GliaSite® radiation therapy system, the world's only balloon catheter device used in the treatment of brain cancer, has earned the European CE Mark, allowing immediate sale in 31 European countries. The system's balloon catheter is a landmark technology that allows physicians to treat more patients than ever before with brachytherapy or internal radiation and provides important benefits over other radiation treatment options.

(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.